Twice-daily hydroxyurea liquid for children with sickle cell disease
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests a new twice-daily liquid form of hydroxyurea (a common SCD medicine) in children ages 9 months to 11 years with sickle cell disease. It will check how the medicine works in the body, if it is safe, and if it helps reduce pain crises and other complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have a specific type of sickle cell disease: HbSS or HbSβ0.
- Your child should be between 9 months and 11 years old.
- Your child must not have taken hydroxyurea (hydroxycarbamide) before.
- Recent blood tests must show healthy levels of certain cells (enough neutrophils, platelets, and hemoglobin).
- No blood transfusions in the past 3 months, and no history of stroke or brain bleeding.
- For kids over 18 months, a recent TCD (head ultrasound) must show a low risk of stroke.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy for sickle cell disease. It uses your own blood stem cells (collected from bone marrow) that are modified in a lab to help produce healthy red blood cells, then given back to you after a short chemotherapy. The goal is to reduce or stop severe complications like pain crises and lung problems.
This trial tests a way to use hydroxyurea more safely and effectively in children with sickle cell anemia. It may help doctors fine-tune dosing to reduce complications and side effects.
This study tests how well a higher dose of hydroxyurea works for teenagers with sickle cell anemia living in areas where malaria is common. It looks at safety and how the treatment affects their daily lives.
This trial program studies sickle cell disease and how treatment works, especially for people who are already taking hydroxyurea at a stable, maximum tolerated dose. It may help researchers better understand treatment effects and side effects in real patients.
This study aims to help more people with sickle cell disease in Nigeria start taking hydroxyurea, a medicine that can prevent pain crises and other complications. It will work with clinics to make it easier for patients to get and stay on this treatment.
This study looks at how people of Nigerian descent with sickle cell disease respond to hydroxyurea, a medicine that helps prevent painful episodes. The goal is to see how your genetic makeup affects how the drug works so that doctors can find the best dose for you.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.